MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
1989 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
254 M |
Market Cap[1] |
$ 7.92 B |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
ADC Therapeutics SA
ADCT
|
$ 1.31 | 6.5 % | $ 166 M | NYSE |  Schweiz |
 |
ADMA Biologics
ADMA
|
$ 9.7 | 3.21 % | $ 2.31 B | Nasdaq Global Market | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 27.89 | 0.3 % | $ 4.23 B | Nasdaq Global Select Market,SPB | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 13.3 | 1.06 % | $ 364 M | Nasdaq Global Market,SPB |  Israel |
 |
AbbVie
ABBV
|
$ 265.08 | 0.02 % | $ 469 B | NYSE,SPB | USA |
 |
Axsome Therapeutics
AXSM
|
$ 193.45 | 0.24 % | $ 9.62 B | Nasdaq Global Market,SPB | USA |
 |
Aytu BioScience
AYTU
|
$ 2.28 | 2.24 % | $ 28.1 M | Nasdaq Capital Market | USA |
 |
Adagene
ADAG
|
$ 2.97 | 0.62 % | $ 175 M | Nasdaq Global Market |  China |
 |
Abeona Therapeutics
ABEO
|
$ 5.53 | 2.65 % | $ 293 M | Nasdaq Capital Market | USA |
 |
Adial Pharmaceuticals
ADIL
|
$ 4.04 | 0.24 % | $ 2.7 M | Nasdaq Capital Market | USA |
 |
Evelo Biosciences
EVLO
|
- | -14.46 % | $ 27.9 M | Nasdaq Global Select Market | USA |
 |
BioMarin Pharmaceutical
BMRN
|
$ 62.21 | 0.06 % | $ 11.9 B | Nasdaq Global Select Market,SPB | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.85 | 0.2 % | $ 929 M | Nasdaq Global Select Market |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 2.16 | 0.45 % | $ 3.56 M | NYSE American | Israel |
 |
Achieve Life Sciences
ACHV
|
$ 7.83 | 0.87 % | $ 341 M | Nasdaq Capital Market | USA |
 |
Catalyst Biosciences
CBIO
|
$ 14.19 | 1.17 % | $ 1.27 B | Nasdaq Capital Market | USA |
 |
Amryt Pharma plc
AMYT
|
- | - | $ 621 M | Nasdaq Global Select Market |  Britain |
 |
C4 Therapeutics
CCCC
|
$ 3.08 | 0.3 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Codexis
CDXS
|
$ 1.38 | 0.72 % | $ 120 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Cerus Corporation
CERS
|
$ 2.6 | 4.3 % | $ 496 M | Nasdaq Global Market | USA |
 |
Coherus BioSciences
CHRS
|
$ 1.26 | 1.48 % | $ 148 M | Nasdaq Global Market | USA |
 |
Celldex Therapeutics
CLDX
|
$ 31.12 | 0.28 % | $ 2.07 B | Nasdaq Global Select Market | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
$ 4.04 | 4.94 % | $ 49.3 M | Nasdaq Capital Market | Israel |
 |
AbCellera Biologics
ABCL
|
$ 12.31 | 0.12 % | $ 3.68 B | Nasdaq Global Select Market | Canada |
 |
Aclaris Therapeutics
ACRS
|
$ 5.26 | 2.69 % | $ 645 M | Nasdaq Global Select Market | USA |
 |
Фармсинтез
LIFE
|
- | - | - | MOEX |  Russia |
 |
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | USA |
 |
Cocrystal Pharma
COCP
|
$ 1.19 | 1.26 % | $ 13.4 M | Nasdaq Capital Market | USA |
 |
Collegium Pharmaceutical
COLL
|
$ 22.45 | 1.05 % | $ 711 M | Nasdaq Global Select Market | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 112.94 | 3.29 % | $ 11.7 B | Nasdaq Capital Market,SPB | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | Nasdaq Global Select Market | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 7.74 | 0.19 % | $ 103 M | Nasdaq Global Market | USA |
 |
Cardiff Oncology
CRDF
|
$ 1.31 | 0.74 % | $ 87.6 M | Nasdaq Capital Market | USA |
 |
Curis
CRIS
|
$ 0.95 | 0.98 % | $ 12.5 M | Nasdaq Global Market | USA |
 |
CorMedix
CRMD
|
$ 7.69 | 0.06 % | $ 554 K | Nasdaq Global Market | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 55.76 | 1.2 % | $ 5.01 B | Nasdaq Global Market,SPB | Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
$ 12.54 | 8.21 % | $ 990 M | Nasdaq Global Market | USA |
 |
Concert Pharmaceuticals
CNCE
|
- | - | $ 401 M | Nasdaq Global Market | USA |
 |
Cue Biopharma
CUE
|
$ 31.71 | 2.62 % | $ 3 B | Nasdaq Capital Market,SPB | USA |
 |
CEL-SCI Corporation
CVM
|
$ 1.68 | 0.59 % | $ 13.5 M | NYSE American,SPB | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 65.81 | 0.04 % | $ 7.9 M | Nasdaq Global Select Market,SPB | USA |
 |
Axon Enterprise
AXON
|
$ 450.61 | 1.61 % | $ 35.2 B | Nasdaq Global Select Market,SPB | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
DiaMedica Therapeutics
DMAC
|
$ 7.56 | 7.16 % | $ 355 M | Nasdaq Capital Market | USA |
 |
Denali Therapeutics
DNLI
|
$ 20.46 | 5.52 % | $ 3.53 B | Nasdaq Global Select Market,SPB | USA |
 |
Precision BioSciences
DTIL
|
$ 6.36 | 10.62 % | $ 81.6 M | Nasdaq Global Select Market | USA |
 |
Dyadic International
DYAI
|
$ 0.41 | 3.72 % | $ 14.8 M | Nasdaq Capital Market | USA |
 |
Editas Medicine
EDIT
|
$ 2.69 | 0.17 % | $ 239 M | Nasdaq Global Select Market,SPB | USA |
 |
Edesa Biotech
EDSA
|
$ 3.97 | 1.46 % | $ 22.5 M | Nasdaq Capital Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.